Physician profile
Michel E Akl
NPI 1154380145
$90,479.56
in general payments reported to CMS, 2019-2025
25 companies · $41K in 2025
The $41K reported for 2025 was more than what 95% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,401 · 2020: $1,410 · 2021: $3,052 · 2022: $3,229 · 2023: $9,440 · 2024: $28K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $6,029 · Travel and Lodging: $5,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,653.00 |
| Food and Beverage | $6,028.56 |
| Travel and Lodging | $5,705.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $41,145.68 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $38,240.86 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,638.88 | 2019-2025 | Dupixent |
| Pfizer INC. | $2,589.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,454.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.54 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $853.69 | 2021-2025 | Tezspire |
| Optinose US, INC. | $484.77 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $473.65 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.08 | 2021-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $121.21 | 2025 | |
| Aimmune Therapeutics, INC. | $48.55 | 2021 | |
| Kaleo, INC. | $37.65 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.81 | 2022 | |
| Alk-Abello, INC | $29.01 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $25.61 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $25.28 | 2020 | |
| Merck Sharp & Dohme LLC | $25.23 | 2019 | |
| Grifols USA, LLC | $20.13 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $16.66 | 2025 | Neffy |
| Mylan Specialty L.P. | $16.27 | 2022 | |
| Horizon Therapeutics Plc | $15.17 | 2022 | |
| Biocryst US Sales Co., LLC | $14.70 | 2022 | |
| Genentech USA, INC. | $14.07 | 2023 | Xolair |
| Circassia INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Akl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.